



Contents

Preface iii

Contributors ix

1. Status and Applicability of U.S. Regulations: Current Good Manufacturing Practices in Manufacturing, Processing, Packaging, and Holding of Drugs 1
Joseph D. Nally
2. Finished Pharmaceuticals: General Provisions Subpart A 13
Joseph D. Nally
3. Organization and Personnel: Subpart B 25
Janice W. Cochran and Joseph D. Nally
4. Buildings and Facilities: Subpart C 37
Robert Del Cielo
5. Equipment: Subpart D 51
Robert Del Cielo, Joseph T. Busfield, and Steven Ostrove
6. Control of Components and Drug Product Containers and Closures: Subpart E 71
Erigen R. Sibille
7. Production and Process Controls: Subpart F 83
Joseph D. Nally and Michael D. Karaim
8. Packaging and Labeling Control: Subpart G 115
Erigen R. Sibille
9. Holding and Distribution: Subpart H 143
Joseph D. Nally
10. Laboratory Controls: Subpart I 149
Wayne J. DeWitte and Alex M. Hoinowski
11. Records and Reports: Subpart J 169
Erigen R. Sibille, Steven Ostrove, Joseph D. Nally, and Laura L. Nally
12. Returned and Salvaged Drug Products: Subpart K 199
Joseph D. Nally

- 13. Repacking and Relabeling** 203
Joseph D. Nally
- 14. Quality Systems and Risk Management Approaches** 215
Joseph D. Nally and Laura L. Nally
- 15. Clinical Trial Supplies and Current Good Manufacturing** 227
Graham Bunn
- 16. Contracting and Outsourcing** 239
Graham Bunn
- 17. Active Pharmaceutical Ingredients** 251
P. Denis Celentano
- 18. Bulk Pharmaceutical Excipient GMPs** 259
Irwin Silverstein
- 19. Recalls, Warning Letters, Seizures and Injunctions:
CGMP Enforcement Alternatives in the United States** 269
Joseph D. Nally
- 20. Controlled Substances Safeguards (21 CFR 1300, et seq.)** 281
Joseph D. Nally
- 21. The Inspection Procedure for Compliance in the United States:
The Regulatee Is Inspected; The Rationale for Inspection (21 USC 373, 374)** 285
Joseph D. Nally
- 22. FDA Pre-Approval Inspections/Investigations: The Road from Scale-Up
and Post-Approval Changes to the Food and Drug Modernization Act** 319
Joseph D. Nally
- 23. Worldwide Good Manufacturing Practices** 335
Joseph D. Nally
- 24. Quality Approaches: ISO 9000, Malcolm Baldrige, and Six Sigma** 349
Joseph D. Nally
- Appendix A. Center for Drug Evaluation and Research: List of Guidance Documents** 359
- Appendix B. ICH Guidelines** 383
- Appendix C. Food and Drug Administration (FDA)/Office Regulatory Affairs (ORA)
Compliance Policy Guides** 385
- Index* 391